Pulse Biosciences, Inc. , a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablationtm (nano-PFA or nsPFAtm) technology, today announced plans to present at the upcoming TD Cowen ...
Piper Sandler lowered the firm’s price target on PacBio (PACB) to $2 from $2.50 following quarterly results. The firm keeps a Neutral rating on ...
In a report released today, David Westenberg from Piper Sandler reiterated a Hold rating on Pacific Biosciences (PACB – Research Report), with ...
18h
Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) had its price target dropped by research analysts at The ...
Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report) was the target of unusually large options trading activity on Tuesday. Investors acquired 31,944 call options on the stock. This ...
Q4 2024 Earnings Call Transcript February 13, 2025 Pacific Biosciences of California, Inc. beats earnings expectations.
Pacific Biosciences of California, Inc. ( NASDAQ: PACB) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Todd Friedman - Senior Director, Finance and Investor Relations Christian Henry - ...
CEO Christian Henry highlighted Q4 2024 revenue of $39.2 million, driven by the shipment of 23 Revio systems and the early shipment of seven Vega benchtop platforms, which exceeded schedule. Full-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback